These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32131141)

  • 1. Management of recalcitrant vitiligo in Vogt-Koyanagi-Harada syndrome: Adjuvant ablative fractional laser.
    Botsali A; Caliskan E
    Pediatr Dermatol; 2020 May; 37(3):514-516. PubMed ID: 32131141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease.
    Bayer ML; Chiu YE
    Pediatr Dermatol; 2017 Mar; 34(2):204-205. PubMed ID: 27981622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Factors Associated With Efficacy and Adverse Events of Fractional Erbium:YAG Laser-Assisted Delivery of Topical Betamethasone for Stable Vitiligo: A Retrospective Analysis.
    Huang C; Li P; Wang B; Deng Y; Li J; Mao M; Jian D
    Lasers Surg Med; 2020 Sep; 52(7):590-596. PubMed ID: 31820470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory vitiligo in Vogt-Koyanagi-Harada disease.
    Tsuruta D; Hamada T; Teramae H; Mito H; Ishii M
    J Am Acad Dermatol; 2001 Jan; 44(1):129-31. PubMed ID: 11148490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment protocols and efficacy of combined laser with medical treatment modalities in vitiligo.
    Mohammadi S; Amiri R; Khalili M; Iranmanesh B; Aflatoonian M
    J Cosmet Dermatol; 2022 Aug; 21(8):3272-3291. PubMed ID: 34766697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study the effect of erbium:YAG laser plus topical 5-flurouracil in stable vitiligo resistant to NB-UVB phototherapy.
    Doghaim NN; El-Tatawy RA; Ismail MA; Ali DAM; El Attar YA
    J Cosmet Dermatol; 2020 Jan; 19(1):122-130. PubMed ID: 31571367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of fractional erbium-YAG laser, microneedling, platelet-rich plasma in localized stable vitiligo patients: randomized clinical trial.
    Abdel-Hamid S; Ibrahim HM; Hameed AM; Hegazy EM
    Arch Dermatol Res; 2024 Jun; 316(7):399. PubMed ID: 38878236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vitiligo revealing Vogt -Koyanagi-Harada disease].
    Amraoui ME; Zemmez Y; Bouhamidi A; Frikh R; Hjira N; Boui M
    Pan Afr Med J; 2017; 27():220. PubMed ID: 28979622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vogt-Koyanagi-Harada syndrome variant.
    Dewan S; Chisholm IA
    Can J Ophthalmol; 1989 Apr; 24(3):109-11. PubMed ID: 2731070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease.
    Inomata H; Rao NA
    Am J Ophthalmol; 2001 May; 131(5):607-14. PubMed ID: 11336935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of High-Dose Fractional Erbium: Yttrium Aluminium Garnet Laser in Stable Vitiligo.
    Botsali A; Caliskan E
    Photobiomodul Photomed Laser Surg; 2021 Sep; 39(9):600-606. PubMed ID: 34546107
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome.
    Forster DJ; Rao NA; Hill RA; Nguyen QH; Baerveldt G
    Ophthalmology; 1993 May; 100(5):613-8. PubMed ID: 8098519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugiura's sign. Perilimbal vitiligo in the Vogt-Koyanagi-Harada syndrome.
    Friedman AH; Deutsch-Sokol RH
    Ophthalmology; 1981 Nov; 88(11):1159-65. PubMed ID: 7335323
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversal of poliosis and vitiligo following Vogt-Koyanagi-Harada disease.
    Tabbara KF
    Arch Ophthalmol; 2012 Mar; 130(3):394-6. PubMed ID: 22411673
    [No Abstract]   [Full Text] [Related]  

  • 15. Intratympanic steroid use for hearing salvage in Vogt-Koyanagi-Harada syndrome.
    Pelosi S; Chandrasekhar SS
    Ear Nose Throat J; 2011 Dec; 90(12):574-7. PubMed ID: 22180111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linear immunoglobulin A/immunoglobulin G bullous dermatosis associated with Vogt-Koyanagi-Harada disease.
    Yanagihara S; Mizuno N; Naruse A; Tateishi C; Tsuruta D; Ishii M
    J Dermatol; 2011 Aug; 38(8):798-801. PubMed ID: 21545501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary study on the treatment of vitiligo with carbon dioxide fractional laser together with tacrolimus.
    Chen W; Zhou Y; Huang FR; Luo D; Wang DG
    Lasers Surg Med; 2018 Oct; 50(8):829-836. PubMed ID: 29635693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vogt-koyanagi-harada syndrome.
    Fang W; Yang P
    Curr Eye Res; 2008 Jul; 33(7):517-23. PubMed ID: 18600484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vogt-Koyanagi-Harada syndrome: review of clinical features.
    Pan D; Hirose T
    Semin Ophthalmol; 2011; 26(4-5):312-5. PubMed ID: 21958180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractional Er:YAG laser assisting topical betamethasone solution in combination with NB-UVB for resistant non-segmental vitiligo.
    Yan R; Yuan J; Chen H; Li YH; Wu Y; Gao XH; Chen HD
    Lasers Med Sci; 2017 Sep; 32(7):1571-1577. PubMed ID: 28710660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.